查詢結果分析
相關文獻
頁籤選單縮合
題 名 | Radiation Recall Pneumonitis Induced by Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor in Patients with Advanced Nonsmall-cell Lung Cancer |
---|---|
作 者 | Chiang, Chi-lu; Chen, Yi-wei; Wu, Mei-han; Huang, Hsu-ching; Tsai, Chun-ming; Chiu, Chao-hua; | 書刊名 | Journal of the Chinese Medical Association |
卷 期 | 79:5 2016.05[民105.05] |
頁 次 | 頁248-255 |
分類號 | 415.46 |
關鍵詞 | Epidermal growth factor receptor; Nonsmall-cell lung cancer; Radiotherapy; Radiation recall pneumonitis; Tyrosine kinase inhibitor; |
語 文 | 英文(English) |
英文摘要 | Background Radiation recall pneumonitis (RRP) is a special form of radiation pneumonitis precipitated by certain pharmacological agents. Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is an effective treatment for advanced nonsmall-cell lung cancer (NSCLC) and has been reported as a potent radiation sensitizer. The incidence and general characteristics of EGFR-TKI-related RRP in patients with NSCLC remain unclear. Methods Clinical records and serial chest images of consecutive patients with advanced NSCLC who had received thoracic radiotherapy (TRT) and EGFR-TKI treatment were retrospectively reviewed. EGFR-TKI-related RRP was diagnosed according to history, clinical manifestations, and radiographic characteristics. Potential risk factors were analyzed. Results In total, 160 patients with NSCLC who received EGFR-TKI after TRT were identified. Of these patients, seven (4.4%) developed EGFR-TKI-related RRP. The median time interval between the end of radiotherapy and RRP was 124 days (range, 80–635 days) and that between the initiation of EGFR-TKI and RRP was 43 days (range, 18–65 days). No risk factor for the development of RRP was identified except that patients in whom EGFR-TKI was initiated within 90 days after the completion of radiotherapy had significantly higher rates of RRP than those of patients who began receiving EGFR-TKI treatment after 90 days (21% vs. 2.1%, p = 0.005). Conclusion In patients with NSCLC who have a history of TRT, treatment with EGFR-TKI may induce not only interstitial lung disease but also RRP. Physicians should be aware of both unexpected adverse events when using EGFR-TKI. |
本系統中英文摘要資訊取自各篇刊載內容。